CompletedNCT00152022
Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.
Medication studyAges 18–55
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: April 25, 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 412
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00152022
- Official title
Show the full official title
A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD).
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Shire.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT03785223
Methylphenidate Hydrochloride Controlled Release Capsules for ADHD
Canada
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
Belgium, Denmark, Germany, + 2 others
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.